Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights

References

• Padma VV. An overview of targeted cancer therapy. Biomedicine 2015;5:19–6.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics 2016. CA: Cancer J Clin 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 2013;140:3079–93.
   PubMed Web of Science ®Google Scholar
• Ingham M, Schwartz GK. Cell-cycle therapeutics come of age. J. Clin. Oncol 2017;35:2949–59.
   PubMed Web of Science ®Google Scholar
• Cheng W, Yang Z, Wang S, et al. Q. Recent development of CDK inhibitors: an overview of CDK/inhibitor co-crystal structures. Eur J Med Chem 2019;164:615–39.
   PubMed Web of Science ®Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015;14:130–46.
   PubMed Web of Science ®Google Scholar
• Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep 2019;21:25.
   PubMed Web of Science ®Google Scholar
• Reck M, Horn L, Novello S, et al. Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in patients with extensive-disease small cell lung cancer. J Thorac Oncol 2019;14:701–11.
   PubMed Web of Science ®Google Scholar
• Niu Y, Xu J, Sun T. Cyclin-dependent kinases 4/6 inhibitors in breast cancer: current status, resistance, and combination strategies. J Cancer 2019;10:5504–17.
   PubMed Web of Science ®Google Scholar
• Ritchie TJ, Macdonald SJ, Peace S, et al. The developability of heteroaromatic and heteroaliphatic rings–do some have a better pedigree as potential drug. Med Chem Comm 2012;3:1062–9.
   Google Scholar
• Ahmed EM, Hassan MS, El-Malah AA, Kassab AE. New pyridazine derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents; design, synthesis and biological evaluation. Bioorg Chem 2020;95:103497.
   PubMed Web of Science ®Google Scholar
• Barberot C, Moniot A, Allart-Simon I, et al. Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents. Eur J Med Chem 2018;146:139–46.
   PubMed Web of Science ®Google Scholar
• Costas T, Besada P, Piras A, et al. New pyridazinone derivatives with vasorelaxant and platelet antiaggregatory activities. Bioorg Med Chem Lett 2010;20:6624–7.
   PubMed Web of Science ®Google Scholar
• Rathish IG, Javed K, Bano S, et al. Synthesis and blood glucose lowering effect of novel pyridazinone substituted benzenesulfonylurea derivatives. Eur J Med Chem 2009;44:2673–8.
   PubMed Web of Science ®Google Scholar
• Roth GJ, Heckel A, Kley JT, et al. Design, synthesis and evaluation of MCH receptor 1 antagonists-Part II: optimization of pyridazines toward reduced phospholipidosis and hERG inhibition. Bioorg. Med. Chem. Lett 2015;25:3270–4.
   PubMed Web of Science ®Google Scholar
• Costas-Lago MC, Besada P, Rodríguez-Enríquez F, et al. Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors. Eur J Med Chem 2017;139:1–11.
   PubMed Web of Science ®Google Scholar
• Kilic B, Gulcan HO, Aksakal F, et al. Design and synthesis of some new carboxamide and propanamide derivatives bearing phenylpyridazine as a core ring and the investigation of their inhibitory potential on in-vitro acetylcholinesterase and butyrylcholinesterase. Bioorg Chem 2018;79:235–49.
   PubMed Web of Science ®Google Scholar
• Tan OU, Ozadali K, Yogeeswari P, et al. Synthesis and antimycobacterial activities of some new N-acylhydrazone and thiosemicarbazide derivatives of 6-methyl-4,5-dihydropyridazin-3(2H)-one. Med Chem Res 2012;21:2388–94.
   Web of Science ®Google Scholar
• Li D, Zhan P, Liu H, et al. Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. Bioorg Med Chem 2013;21:2128–34.
   PubMed Web of Science ®Google Scholar
• Jaballah MY, Serya RT, Abouzid K. Pyridazine based scaffolds as privileged structures in anti-cancer therapy. Drug Res (Stuttg) 2017;67:138–48.
   PubMed Web of Science ®Google Scholar
• Bongartz JP, Stokbroekx R, Van der Aa M, et al. Synthesis and anti-angiogenic activity of 6-(1,2,4-thiadiazol-5-yl)-3-amino pyridazine derivatives. Bioorg Med ChemLett 2002;12:589–91.
   Web of Science ®Google Scholar
• Abouzid KA, Khalil NA, Ahmed EM, Mohamed KO. [(3-[(6-Arylamino)pyridazinylamino]benzoic acids: design, synthesis and in vitro evaluation of anticancer activity. Arch Pharm Res 2013;36:41–50.
   PubMed Web of Science ®Google Scholar
• Kim C, Park EH, Park MS. Novel alkylaminopyridazine derivatives: synthesis and their anti-proliferative effects against MCF-7 cells. Bull Korean Chem Soc 2013;34:3317–21.
   Web of Science ®Google Scholar
• Kim C, Kim SB, Park MS. Synthesis of novel 3-allylseleno-6-alkylthiopyridazines: their anticancer activity against MCF-7 cells. Arch Pharm Res 2014;37:452–8.
   PubMed Web of Science ®Google Scholar
• Park HS, Kim C, Park MS. Discovery and synthesis of novel allylthioaralkylthiopyridazines: their antiproliferative activity against MCF-7 and Hep3B cells. Arch Pharm Res 2015;38:791–800.
   PubMed Web of Science ®Google Scholar
• George RF, Fouad MA, Gomaa IEO. Synthesis and cytotoxic activities of some pyrazoline derivatives bearing phenyl pyridazine core as new apoptosis inducers. Eur J Med Chem 2016;112:48–59.
   PubMed Web of Science ®Google Scholar
• Elmeligie S, Ahmed EM, Abuel-Maaty SM, et al. Design and synthesis of pyridazine containing compounds with promising anticancer activity. Chem Pharm Bull 2017;65:236–47.
   PubMed Web of Science ®Google Scholar
• Sengmany S, Sitter M, Léone E, et al. Synthesis and biological evaluation of 3-amino-, 3-alkoxy- and 3-aryloxy-6-(hetero)arylpyridazines as potent antitumor agents. Bioorg Med Chem Lett 2019;29:755–60.
   PubMedGoogle Scholar
• Jaballah MY, Serya RAT, Saad N, et al. Towards discovery of novel scaffold with potent antiangiogenic activity; design, synthesis of pyridazine based compounds, impact of hinge interaction, and accessibility of their bioactive conformation on VEGFR-2 activities. J Enzyme Inhib Med Chem 2019;34:1573–89.
   PubMedGoogle Scholar
• Ali YM, Ismail MF, Abu El‐Azm FS, Marzouk MI. Design, synthesis, and pharmacological assay of novel compounds based on pyridazine moiety as potential antitumor agents. J Heterocycl Chem 2019;56:2580–91.
   Web of Science ®Google Scholar
• Landge SM, Török B. Highly enantioselective organocatalytic addition of ethyl trifluoropyruvate to ketones with subzero temperature microwave activation. Catal Lett 2009;131:432–9.
   Web of Science ®Google Scholar
• Sibgatulin DA, Volochnyuk DM, Kostyuk AN. A convenient synthesis of 4-trifluoromethyl-(2H)-pyridazin-3-ones from methyl 3,3,3-trifluoropyruvate. Synlett 2005;2005:1907–11.
   Google Scholar
• Siddiqui FA, Alam C, Rosenqvist P, et al. PDE6D inhibitors with a new design principle selectively block K-ras activity. ACS Omega 2020;5:832–42.
   PubMed Web of Science ®Google Scholar
• Skehan P, Storeng R, Scudiero D, et al. New colorimetric cyto-toxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107–12.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. Swiss TargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucl Acids Res 2019;47:357–64.
   PubMed Web of Science ®Google Scholar
• Gfeller D, Michielin O, Zoete V. Shaping the interaction landscape of bioactive molecules. Bioinformatics 2013;29:3073–9.
   PubMed Web of Science ®Google Scholar
• Ding L, Cao J, Lin W, et al. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int J Mol Sci 2020;21:1960.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7:42717.
   PubMed Web of Science ®Google Scholar
• Daina A, Zoete V. A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem 2016;11:1117–21.
   PubMed Web of Science ®Google Scholar
• Veber DF, Johnson SR, Cheng HY, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45:2615–23.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev 2001;46:3–26.
   PubMed Web of Science ®Google Scholar
• Egan WJ, Merz KM, Baldwin JJ. Prediction of Drug Absorption Using Multivariate Statistics. J. Med. Chem 2000;43:3867–77.
   PubMed Web of Science ®Google Scholar
• Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1999;1:55–68.
   PubMed Web of Science ®Google Scholar
• Muegge I, Heald SL, Brittelli D. Simple selection criteria for drug-like chemical matter. J Med Chem 2001;44:1841–6.
   PubMed Web of Science ®Google Scholar
• Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010;53:2719–40.
   PubMed Web of Science ®Google Scholar
• Ruth B, Schipani A, James D, et al. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMedChem 2008;3:435–44.
   PubMed Web of Science ®Google Scholar
• Sabt A, Abdelhafez OM, El-Haggar RS, et al. Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: Synthesis, in vitro biological evaluation, and QSAR studies. J Enzym Inhib Med Chem 2018;33:1095–107.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Hassan GS, Al-Rashood ST, et al. Synthesis and in vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents. J Enzym Inhib Med Chem 2019;34:322–32.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Hassan GS, Al-Rashood ST, et al. Marine-inspired bis-indoles possessing antiproliferative activity against breast cancer; design, synthesis, and biological evaluation. Mar Drugs 2020;18:190.
   PubMed Web of Science ®Google Scholar
• Said MA, Eldehna WM, Nocentini A, et al. Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: design, synthesis, and in vitro biological evaluation. Eur J Med Chem 2020;189:112019.
   PubMed Web of Science ®Google Scholar
• Ayaz P, Andres D, Kwiatkowski DA, et al. Conformational adaption may explain the slow dissociation kinetics of roniciclib (BAY 1000394), a type I CDK inhibitor with kinetic selectivity for CDK2 and CDK9. ACS Chem Biol 2016;11:1710–9.
   PubMed Web of Science ®Google Scholar
• Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comp Chem 2010;31:455–61.
   PubMed Web of Science ®Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J Comp Chem 2009;16:2785–91.
   Web of Science ®Google Scholar
• Available online: https://3dsbiovia.com/resource-center/downloads/ [last accessed 10 April 2020].
   Google Scholar